The links inside this blog will take you to pages with information about very small (T1a, and sometimes T1b) HER2-postive breast cancer tumors. The links outside this blog take you to respected organizations.

Inside This Blog:

Retrospective Studies

APT Trial

New Research

Doctor Interviews

Tumor Biology

Trastuzumab, chemotherapy

My Story

Outside This Blog:

NCI Dictionary of Cancer Terms (National Cancer Institute)

NCCN (National Comprehensive Cancer Network)

NCCN Guidelines for Stage I Breast Cancer

ASCO (American Society of Clinical Oncology)

ESMO (European Society for Medical Oncology)

ESMO Guidelines for Primary Breast Cancer: these guidelines say T1b cases should receive chemotherapy and trastuzumab, while NCCN guidelines state T1b cases should consider it.

Cancer Commons: the people who run this site offer free second opinions, which often are not covered by medical insurance. I had a great experience with this awesome service. One of the 10 opinions on my “medically interesting” case came from a highly regarded scientist on this site.

And specifically for HER2-positive cancers of all sizes, the chief scientist at Cancer Commons wrote an article about trastuzumab and the drugs that followed, and current drugs in the pipeline. That article is here.



The information contained in this blog is not intended to be used for medical diagnosis or treatment. It should not be used in place of the advice of your doctor or other qualified health care provider.